SCHEMBL38152

SCHEMBL38152

CCOC(=O)c1cc(N)c(C(=O)OCC)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.60
ALDH1A1 P00352 8/20 0.60
RAB9A P51151 7/20 0.60
KDM4E B2RXH2 6/20 0.60
NPC1 O15118 6/20 0.60
SMN1; SMN2 Q16637 6/20 0.60
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
HPGD P15428 5/20 0.60
HSD17B10 Q99714 4/20 0.60
CYP1A2 P05177 2/20 0.57
TP53 P04637 1/20 0.57
CASP3 P42574 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
RECQL P46063 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10712475 0.84 MAPT (0.61) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL1883586 0.82 MAPT (0.56) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL1531268 0.81 MAPT (0.63) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL7842072 0.80 ALDH1A1 (0.62) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL6119541 0.79 ALDH1A1 (0.56) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL8815118 0.79 MAPT (0.56) MAPTALDH1A1RAB9AKDM4ENPC1
Hydrochloric Acid SCHEMBL11017093 0.78 MAPT (0.56) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL3885696 0.78 KDM4E (0.45) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL3239031 0.77 KDM4E (0.54) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL12963136 0.76 GAA (0.69) MAPTALDH1A1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012004900-A1 THIENOPYRIMIDINE COMPOUNDS ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 WO disclosed
EP-1370562-A1 THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-12-17 EP disclosed
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed
WO-2002064598-A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 MAPT 4800/4885ALDH1A1 812/4885RAB9A 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.